NCT01481129View on ClinicalTrials.gov

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2014

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Akt Inhibitor MK2206

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (9)

13273

Institut Paoli Calmettes, Marseille

33076

Institut Bergonie Cancer Center, Bordeaux

59037

Hospital Claude Huriez Chru, Lille

69310

Centre Hospitalier Lyon-Sud, Pierre-Bénite

69373

Centre Leon Berard, Lyon

75010

Hopitaux de Paris, Vellefaux

Hopital Saint Louis, Paris

94000

Henri Mondor University-Hospital Center, Créteil

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01481129 - Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter